Last updated: December 19, 2023
Sponsor: University of Virginia
Overall Status: Active - Recruiting
Phase
4
Condition
Stress
Hormone Deficiencies
Hypertriglyceridemia
Treatment
Liraglutide
Exercise
Clinical Study ID
NCT03883412
20320
Ages 21-60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 21-60
- A1C ≤ 8.5%
- Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
- On stable dose of oral hypoglycemic agents >4 months
- On stable dose of other medications for >4 months
Exclusion
Exclusion Criteria:
- Taking Insulin
- Smoking presently or in the past 6 months
- BP >160/90
- BMI >35
- Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
- History of congestive heart failure, ischemic heart disease, severe pulmonary disease,liver or kidney disease.
- Any vascular disease such as myocardial infarction, stroke, peripheral vasculardisease
- Presence of an intracardiac or intrapulmonary shunt (we will screen for this byauscultation during the physical exam by PI).
- Pregnant or breastfeeding.
- Known hypersensitivity to perflutren (contained in Definity)
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Liraglutide
Phase: 4
Study Start date:
February 28, 2019
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
University of Virginia
Charlottesville, Virginia 22906
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.